Sung-Yun Pai, MD


Sung-Yun Pai, MD, on High T-Cell Reconstitution in X-SCID With Lentiviral Gene Therapy

The senior investigator at the National Cancer Institute Center for Cancer Research discussed updated data from a phase 1/2 trial presented at ASGCT 2023.

Dan Pollyea, MD, MS


Allogeneic Stem Cell Transplant for Acute Myeloid Leukemia

The hematologist from UC Health discussed the role of allogeneic stem cell transplant at first remission based on risk stratification.

Alba Gonzalez-Junca, PhD


Alba Gonzalez-Junca, PhD, on Logic-gated CAR-NK Cell Development

The associate director of Research at Senti Biosciences discussed the company's research on using logic-gated CAR-NK cells for the treatment of AML and solid tumors.

Matthew B. Harms, MD


Matthew B. Harms, MD, on the Necessity of Tracking Gene Mutations in ALS

The associate professor of neurology at Columbia University spoke about the importance of identifying patients with ALS-associated gene mutations as early as possible.

Saad Z. Usmani, MD, Atrium Health


Dr. Usmani on the Potential Utility of Allogeneic CAR T-Cell Therapy in Multiple Myeloma

Saad Z. Usmani, MD, FACP, discusses the potential utility of allogeneic CAR T-cell therapy in multiple myeloma.

Levi Gray-Rupp, PhD


Levi Gray-Rupp, PhD, on Using Integrated Circuit T-Cells Against Solid Tumors

The senior director of immunology at Arsenal Bio discussed advantages of ICTs and the company’s clinical trial in ovarian cancer.

Courtney Flaherty


Mantle Cell Lymphoma Outcomes May Improve With Bispecific CD20/CD19-targeted CAR T-cell Therapies

Nirav N. Shah, MD, associate professor at the Medical College of Wisconsin in Milwaukee, discussed the evaluation of LV20.19 CAR in MCL, as well as key efficacy and safety data on the therapy to date.

Thomas G. Martin, MD


Thomas Martin, MD, on Exciting Cell Therapy Options in Multiple Myeloma

The clinical professor of medicine, Helen Diller Family Comprehensive Cancer Center, UCSF, discussed cilta-cel and upcoming cell therapies.

Stacy Lindborg, PhD


Stacy Lindborg, PhD, on Addressing Unmet Needs in ALS With Cell Therapy

The co-CEO of BrainStorm Cell Therapeutics spoke about the current standards of care in ALS and the potential of NurOwn to address unmet needs.

Maria Escolar, MD


Maria Escolar, MD, on Combining HSCT With Gene Therapy in Krabbe Disease

The chief medical officer of Forge Biologics discussed the potential advantages of the investigational combination therapy approach.

Christian S. Hinrichs, MD


Christian Hinrichs, MD, on Improving Solid Tumor Targeting With Engineered T-Cell Therapies

The chief of cancer immunotherapy at Rutgers Cancer Institute discussed clinical results with different cell therapy approaches.

Ralph Laufer, PhD


Gene Therapy for GM1 Gangliosidosis: Latest Updates

Ralph Laufer, PhD, chief scientific officer, Lysogene, discussed gene therapy programs in GM1 gangliosidosis and Fragile X syndrome.

Alexis Thompson, MD, MPH


Alexis Thompson, MD, MPH, on the Impact of Beti-Cel's Approval in Beta Thalassemia

The primary investigator and chief of hematology at Children’s Hospital of Philadelphia discussed the collaboration and research that went into developing beti-cel.

Samiah Al-Zaidy, MD


Samiah Al-Zaidy, MD, on Gene Therapy for Infantile GM1 Gangliosidosis

Al-Zaidy, the vice president of clinical development and lead on the GM1 Program at Passage Bio, discussed the results of the phase 1/2 Imagine-01 clinical trial of PBGM01.

Philippe Moreau, MD


Promising Outlook in Multiple Myeloma with Cilta-Cel: Philippe Moreau, MD

Philippe Moreau, MD, discussed the CARTITUDE-1 trial's promising results with ciltacabtagene autoleucel read out at the 2021 ASCO Annual Meeting.

Sharon Hesterlee, PhD


Sharon Hesterlee, PhD, on Opening Regulatory Pathways for Ultra-Rare Disease Treatments

The executive vice president and chief research officer of MDA discussed the barriers to FDA approval currently facing those developing treatments for ultra-rare diseases.

Joseph Sullivan, MD


Novel Therapies in Development for Dravet Syndrome

Joseph Sullivan, MD, and Elaine C. Wirrell, MD, discuss new developments for the treatment of Dravet syndrome beyond seizure control including gene editing and therapy.

Elaine C. Wirrell, MD


Novel Therapies in Development for Dravet Syndrome

Joseph Sullivan, MD, and Elaine C. Wirrell, MD, discuss new developments for the treatment of Dravet syndrome beyond seizure control including gene editing and therapy.

Chris Ryan


Axi-Cel Improves Overall Survival in Lymphoma, ZUMA-7 Analysis Shows

Investigators plan to present full results from the OS analysis of the phase 3 ZUMA-7 trial at an upcoming medical meeting.

Takashi Kei Kishimoto, PhD


Re-Dosing With Gene Therapies in Rare Diseases

Takashi Kei Kishimoto, PhD, and Carsten Brunn, PhD, the chief science and executive officers of Selecta Biosciences, discussed the immunogenicity-mitigating properties of ImmTOR.

Kevin Flanigan, MD


Kevin Flanigan, MD, on the Impact of Neuromuscular Disease Gene Therapy Approvals

The director of the center for gene therapy at Nationwide Children's Hospital discussed the prospect of gene therapy approvals in Duchenne muscular dystrophy and the associated challenges that remain to be addressed.

Courtney Young, PhD


Courtney Young, PhD, on Gene Editing Approaches to Treating Neuromuscular Disease

The co-founder and chief executive officer of MyoGene Bio spoke about the company's gene editing therapy for Duchenne muscular dystrophy at MDA’s 2023 conference.

Rebecca Cottman, PhD


Rebecca Cottman, PhD, on Creating Regulated Gene Circuits to Enhance Cell Therapy Cytotoxicity

The scientist at Senti Biosciences discussed developing small molecule-regulated gene circuits.

David Taylor, PhD


Improving Speed and Fidelity of CRISPR/Cas9: Kenneth Johnson, PhD, and David Taylor, PhD

The professors and researchers from The University of Texas at Austin discussed new findings of Cas9 structure and mechanisms.

Marin F. Xavier, MD


Increasing CAR T-cell Use in R/R DLBC Lymphoma: Marin F. Xavier, MD; John M. Burke, MD

Experts discuss recommendations to increase the uptake of CAR T-cell therapies into clinical practice and relapsed/refractory diffuse large B-cell lymphoma.

Bart P. Leroy, MD, PhD


Bart P. Leroy, MD, PhD, on Aligning IRD Gene Therapy Outcome Measures With Activities of Daily Living

The head of the Department of Ophthalmology at the Center for Medical Genetics at Ghent University Hospital discussed the need to reevaluate requirements for regulatory approval for ophthalmology gene therapies.

André Choulika, PhD


Efficient Gene Editing in Monogenic Diseases

André Choulika, PhD, chief executive officer and cofounder, Cellectis, discussed the company’s expansion into gene therapies.

Stephanie Cherqui, PhD


Stephanie Cherqui, PhD, on Bringing Attention to Cystinosis and Gene Therapy

The associate professor from UC San Diego discussed promising efficacy and safety data from a phase 1/2 trial.

Guoqiang Ai, MD


Weijia Fang, MD, and Guoqiang Ai, MD, on the Future of IMC001 in Gastric and Colorectal Cancer

Fang commented on a limitation of the clinical trial pointed out at the European Society for Medical Oncology (ESMO) 2022 Congress.

© 2023 MJH Life Sciences

All rights reserved.